Early stage European VC firm, Blossom Capital, is fresh from closing a $185M fund— a big jump up on its prior close.

The firm makes just a handful of investments per year, mostly at the Series A stage, working very closely with founders in its portfolio — a strategy it refers to as “high conviction” investing.

One of its chosen few is Inne, a Berlin-based femtech startup that’s building a novel, hormone-tracking subscription product, for fertility-tracking and ‘natural’ contraception.

TechCrunch: How does the fund approach femtech?

Samet: The way we define femtech is products that are built for women. | To read full story, visit https://startuparound.com/read/1580896815.7850263/Blossom-Capital’s-Louise-Samet-talks-hormone-tracking-and-femtech-bets-–-TechCrunch?ref=audio_experience